A Synthetic Aptamer-Drug Adduct for Targeted Liver Cancer Therapy.

PLoS One

Department of Pathology, Immunology and Laboratory Medicine, College of Medicine, University of Florida, Gainesville, Florida, United States of America.

Published: June 2016

AS1411 (previously known as AGRO100) is a 26 nucleotide guanine-rich DNA aptamer which forms a guanine quadruplex structure. AS1411 has shown promising utility as a treatment for cancers in Phase I and Phase II clinical trials without causing major side-effects. AS1411 inhibits tumor cell growth by binding to nucleolin which is aberrantly expressed on the cell membrane of many tumors. In this study, we utilized a simple technique to conjugate a widely-used chemotherapeutic agent, doxorubicin (Dox), to AS1411 to form a synthetic Drug-DNA Adduct (DDA), termed as AS1411-Dox. We demonstrate the utility of AS1411-Dox in the treatment of hepatocellular carcinoma (HCC) by evaluating the targeted delivery of Dox to Huh7 cells in vitro and in a murine xenograft model of HCC.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4629891PMC
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0136673PLOS

Publication Analysis

Top Keywords

synthetic aptamer-drug
4
aptamer-drug adduct
4
adduct targeted
4
targeted liver
4
liver cancer
4
cancer therapy
4
as1411
4
therapy as1411
4
as1411 agro100
4
agro100 nucleotide
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!